US FDA mulls upping risk class for vaginal mesh as lawsuits mount for manufacturers
This article was originally published in SRA
Executive Summary
US Food and Drug Administration advisors are deliberating over whether to reclassify transvaginal meshes used to treat pelvic organ prolapse as high-risk products, after serious complications in patients implanted with the devices prompted calls for stricter regulations1.